Author:
Tupayachi Ortiz Maria Gabriela,Baumlin Nathalie,Yoshida Makoto,Salathe Mathias Andreas
Reference14 articles.
1. N1303K: leaving no stone unturned in the search for transformational therapeutics;S Noel;Journal of Cystic Fibrosis,2018
2. Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence;Y Huang;Am J Respir Crit Care Med,2021
3. CFTR Modulator Therapy in an Individual with Cystic Fibrosis Caused by a N1303K CFTR Variant and Infected With Mycobacterium abscessus;E C Elson;J Pediatr Pharmacol Ther,2022
4. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation;I Sadras;J Cyst Fibrosis